There is a familiar shape to artwork projects. Brand wants a pack that looks like the brand. Regulatory wants a pack that carries every statutory particular in the approved wording. The two negotiate, someone concedes, and the result is a compromise neither side defends with much enthusiasm.

That framing is wrong, and it produces worse outcomes on both counts. Compliance is not a tax on brand. Read the MHRA's labelling guidance closely and it asks for the same things a good designer would ask for: hierarchy, legibility, consistency, restraint. The qualities that stop a pharmacist picking the wrong strength are the qualities that make a pack recognisable at arm's length.

As a pharma packaging company, we see where the argument gets settled: on the line, at three in the morning, when a foil-blocked carton will not take an inkjet code cleanly.

The same qualities serve both ends

Clarity. A pack that presents name, strength and route as a grouped, legible block reduces selection error. It also reads instantly on a shelf, in a drug cupboard, in a photograph on a formulary. Clarity is not the price of compliance; it is the mechanism of recognition.

Consistency. Managing look-alike, sound-alike risk across a portfolio means differentiating strengths and presentations in ways that survive a glance. Done deliberately, that is brand architecture. A family of packs with a stable structure and disciplined differentiation is both a safety control and the thing that makes a portfolio legible to prescribers.

Manufacturability. A carton that erects, fills, closes and codes without intervention is a compliance asset, because fewer stoppages mean fewer manual interventions, fewer reconciliation queries and fewer defects. It is also a brand asset, because the pack the patient opens is square, uncrushed and correctly coded.

Security. Anti-tampering devices and 2D coding exist for regulatory and patient safety reasons in the markets that mandate them. They also protect the revenue and reputation the brand represents. Nobody has ever had to choose between a pack that resists falsification and a pack that holds its value.

Sustainability. Material reduction and mono-material choices satisfy procurement and patients. They also have to survive qualification: a lighter board with a different stiffness changes carton erection, a different coating changes adhesion, and a recycled fibre content changes print consistency. The environmental case is real, but it becomes real only after the pack has been proven to run.

Adherence is a design responsibility

A medicine that is not taken correctly does not work, and packaging is one of the few points where design directly influences that. Calendarised blisters, clear day markings, legible dosing instructions, pack formats matched to the dispensing interval, opening features usable by patients with limited grip: these are design decisions with clinical consequences.

They are also brand decisions. Patients form an opinion of a product from the physical object they handle twice a day for a year. A pack that is hard to open, hard to read or hard to keep track of is a pack that quietly erodes trust in the medicine. Adherence design is where the safety argument and the brand argument stop being separable.

What a recall costs a brand

Regulatory failure is usually discussed as a compliance cost: retrieval, replacement, investigation, lost batches. The brand cost is larger and lasts longer. A recall attributed to a labelling error becomes a permanent search result, a talking point in tender evaluations and a question in every subsequent audit.

Most labelling recalls trace back to process rather than intent: an artwork version that was not the approved one, a component change made without assessing its effect on print, a proof approved by someone without authority to approve it. Those are governance failures, and governance is the least glamorous and most protective investment a brand owner can make in its packaging.

The specific tension points

Three collisions recur, and each is resolvable if it is surfaced early.

Colour-coding by strength. Brand teams like it because it is clean, memorable and easy to extend across a range. MHRA best practice guidance discourages reliance on colour alone to distinguish strengths, because it encourages selection by colour instead of by reading the name and strength. The resolution is not to abandon colour but to demote it: differentiate primarily by typographic hierarchy and clear numerals, and let colour support rather than carry the distinction.

Minimalism against statutory content. A restrained design language collides with a long list of particulars, an excipient declaration, a Braille panel and a coding area. Space is finite. The answer is to design the mandatory content first, allocate the coding and Braille zones before the visual concept is developed, and treat what remains as the creative space. Concept first, content later is the sequence that produces late redesigns.

Premium finishes against machine performance. Spot UV, soft-touch laminates, metallic foils and heavy varnish all interfere with something. Anti-tamper labels may not adhere reliably to a soft-touch surface. Inkjet codes bead or smear on varnish, and thermal transfer needs a compatible substrate. A DataMatrix printed onto a reflective foil can fail grading even though it looks perfect to the eye. None of this rules out a premium finish. It rules out a premium finish applied across the whole panel without a defined coding window.

The organisational fix: bring your pharma packaging company in earlier

The pattern behind all three is timing. Brand guidelines are set, artwork is developed, regulatory reviews the text, and only then does the pack reach the people who have to run it. Manufacturability input arrives after the decisions that constrain it have been made.

The fix is unglamorous: get regulatory, QA, brand and the packer into the same conversation before artwork sign-off. In practice that means a technical review of the concept while it is still a concept, agreed coding and Braille zones on the cutter guide, a substrate and finish specification confirmed against the machinery that will run it, and version control with one approved master and named approvers.

It costs a few weeks at the front of a project. It saves reprints, requalification and the misery of discovering at validation that the board chosen for its recycled content will not hold a crease.

A packer only ever handed finished artwork can do no more than flag problems. One brought in at concept stage can shape a pack that is compliant, on-brand and manufacturable at once, which is the only version of the trade-off worth having.

Key takeaways

• Compliance and brand pull in the same direction more often than they conflict: clarity, consistency and restraint serve safety and recognition equally.
• Adherence is a design responsibility, and pack usability shapes both clinical outcome and patient trust in the product.
• Labelling recalls usually stem from governance failures in version control and change assessment, and the brand cost outlasts the direct cost.
• Colour-coding by strength, minimalist layouts and premium finishes are the three recurring collision points, and all three are resolvable if raised at concept stage.
• Getting regulatory, QA, brand and the packer into one conversation before artwork sign-off is cheaper than any of the reworks it prevents.

Talk to Central Pharma about getting the pack right first time

Central Pharma is a contract filler and packer to the pharmaceutical, medical device, cell and gene therapy and healthcare sectors, working from a 267,000 sq ft licensed site in Bedford since 2006 under an MHRA MIA and WDA(H), with ISO 9001, ISO 13485, a dedicated QA team and three Qualified Persons. We sit alongside your design team as the manufacturing voice in the room: reviewing artwork against statutory content and against what the line can actually run, controlling versions through to QA sign-off, qualifying the pack on the equipment that will make it, and applying anti-tamper devices and serialisation for export markets. Bring us in at concept stage and the compliant pack, the on-brand pack and the manufacturable pack turn out to be the same pack. Contact us

To stay informed on our latest thinking and technology developments, follow us on LinkedIn.

Contact Us Today

View all news